GSDME and melanoma: Additionally, Erkes and colleagues found that combined BRAF inhibitor and MEK inhibitor treatment causes GSDME‐mediated pyroptosis in BRAFV600E/K ‐mutant melanoma via active caspase‐3, ultimately resulting in HMGB‐1 release to activate antitumor T‐cell responses.39